| IPO Company Profile © ipodata.com |
| Message Board | SEC Filings | Peer IPO Companies |
| DNA Sciences, Inc. |
| 6540 Kaiser Drive, Fremont, CA 94555 * (510) 494-4000 |
| Business Description | The company is a genetics discovery company focused on identifying the genetic basis of diseases susceptibility, disease progression and response to drug treatment. |
|
Filing Information IPO has been | |||
| To Trade As | DNAS (NASNTL) | Industry | Service (SIC 8731) |
| Type of Stock Offered | Common Shares | Filing Date | 1/5/2001 |
| Domestic Shares Filed | 0 | Filing Price | - - |
| Foreign Shares Filed | 0 | Offering Amount | $125,000,000 |
| Company Shares | 0 | Est. Expenses | - - |
| Selling Shrhldrs Shares | 0 | Post-IPO Shares | - - |
| Primary Underwriting Group | ||
| Underwriter Name | Participation | Underwriter Phone |
| Lehman Brothers Incorporated | Lead Manager | (212) 526-8100 |
| CIBC World Markets | Co-manager | (212) 667-7400 |
| Dain Rauscher Wessels | Co-manager | (612) 371-2818 |
| Income Statement and Cash Flow Summary | |||||||
| Prior Audited Income |
Latest Unaudited Income | ||||||
| Full Year Audited Figures | 9 Months Ending | ||||||
| Figures in U.S. millions except per share data | 12/31/1998 | 12/31/1999 | 9/30/1999 | 9/30/2000 | |||
| Revenues | - | - | - | 0.000 | 0.079 | 0.000 | 0.500 |
| Income from Oper. | - | - | - | -0.329 | -7.940 | -5.933 | -24.739 |
| Net Income | - | - | - | -0.348 | -7.837 | -5.848 | -23.457 |
| E.P.S | - | - | - | - | -16.010 | -13.430 | -16.590 |
| Revenue Growth (%) | - | - | - | - | - | ||
| Net Income Growth (%) | - | - | - | - | - | ||
| Oper. Profit Margin (%) | - | - | - | - | - | - | - |
| Net Profit Margin (%) | - | - | - | - | - | - | - |
| Cash Flow - Oper. | -5.41 | -4.14 | -11.05 | ||||
| Cash Flow - Inv. | -3.19 | -2.19 | -9.75 | ||||
| Cash Flow - Fin. | 12.08 | 10.49 | 58.20 | ||||
| Balance Sheet Summary and Financial Ratios | |||||
| Balance sheet as of: 9/30/2000 | Financial Ratios | ||||
| Total Assets | 61.45 | Current Assets | 41.54 | Current Ratio | 4.00 |
| Total Liab. | 85.72 | Current Liab. | 10.39 | Debt Ratio | 139.48% |
| Total Equity | -24.26 | Working Cap. | 31.15 | Debt to Equity Ratio | - |
| Cash | 40.88 | Return on Assets | - | ||
| Use Of Proceeds |
The proceeds from the proposed offering will be used to continue and expand genetic discovery programs, maintain and expand the genetic database, commercialize diagnostic tests under development, purchase subscriptions to genomic databases from third parties, make capital expenditures, and for general corporate purposes, including working capital. |
| Legal Counsel Registrar Auditor | |
| Issuer's Law Firm | Cooley Godward Castro Huddleson & Tatum |
| Bank's Law Firm | Fried, Frank, Harris, Shriver & Jacobson |
| Auditor | Ernst & Young |
| Send us feedback if you would like to request that we hyperlink a firm on this page | |
| Principal Shareholders | ||
| Name of Shareholder | % Owned Before | % Owned After |
| Monaco Partners, L.P. | 14.10 | |
| Product Development, Inc. | 11.30 | |
| Brentwood Venture Capital affiliated entities | 10.30 | |
| Apple Tree Partners I, L.P. | 9.00 | |
| Quantum Partners affiliated entities | 7.60 | |
| WebMD Corporation | 6.40 | |
| Domain Partners affiliated entities | 5.70 | |
| Axys Pharmaceuticals, Inc. | 5.60 | |
| Note: represents ownership of 5% or more prior to the offering. | ||